ArticleLeukemia2019

Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.

Yonghui Sun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.